HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 04, April 2018 – Digestive health in the 21st century - Trust your guts       » Food wasted in China could feed 30-50 million       » Chinese scientists analyze human brain's "CPU"       » $150,000 fundraiser launched to sequence South Asian genomes       » Green tea-based drug carriers improve cancer treatment       » Scientists grow liver cancer cells in lab      

BIOBOARD - AUSTRALIA & NEW ZEALAND

LCT Collaborates with Auckland University Centre for
Brain Research to Extend Product Pipeline

Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has initiated a research collaboration with the Centre for Brain Research (CBR) at the University of Auckland. The research collaboration will explore how LCT’s products can reverse human brain neurodegenerative processes associated with pericytes (and other brain cells), which help sustain the blood-brain barrier and other homeostatic and haemostatic functions in the brain.

The agreement has two primary goals. The first is to extend the pipeline for LCT’s lead product NTCELL® by examining the effects of NTCELL on cell cultures derived from human brains with Alzheimer’s disease and Huntington’s disease. The second is to identify other encapsulated cell therapies which may have potential to treat these neurodegenerative disorders by examining whether they can promote neuroprotective effects in the brain.

The research will be undertaken by Auckland UniServices Limited (UniServices), the commercial research company of the University of Auckland, using the breakthrough drug testing and drug target validation platform, Neurovalida. Neurovalida, developed by Professor Mike Dragunow, Distinguished Professor Sir Richard Faull and Associate Professor Maurice Curtis from the CBR, provides human brain-based neuroscience research collaborations, partnerships and services.

CEO of Living Cell Technologies, Dr Ken Taylor, says the agreement enables LCT to benefit from the CBR’s world class capabilities.

“Animal models are of limited use in discovering new treatments for these difficult and increasingly prevalent neurodegenerative diseases. The availability of human tissue cell cultures such as pericytes, and other human brain cells eliminates that problem.”

Director of the CBR, Distinguished Professor Sir Richard Faull, says he is enthusiastic about the project.

“We have been working with Living Cell Technologies with the goal of defining a treatment-directed research project that brings together their expertise in the clinical development of cell-based therapies and our expertise in identifying targets from our knowledge and availability of human brain tissue.

“This is a very exciting collaboration with LCT which has great translational opportunities,” he added.

For further information: www.lctglobal.com.

Source: Living Cell Technologies Limited (LCT)

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy